Trinity Biotech

Trinity Biotech Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Trinity Biotech (TRIB) as of Oct 16, 2026 is 99.74. In the previous year, Cash Conversion Cycle (CCC) was 196.39 — a change of -49.21% (lower).

Cash Conversion Cycle

99.74

YoY

-49.21%

Last updated:

Cash Conversion Cycle (CCC) of Trinity Biotech is 2025 99.74 . Cash Conversion Cycle (CCC) of Trinity Biotech was 2024 196.39 . It decreases by -49.21% lower compared to the previous year.

The Trinity Biotech Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
177.40 USD
Jan 1, 2019
169.41 USD
Jan 1, 2020
233.89 USD
Jan 1, 2021
211.79 USD
Jan 1, 2022
192.75 USD
Jan 1, 2023
228.77 USD
Jan 1, 2024
196.39 USD
Jan 1, 2025
99.74 USD
The Trinity Biotech Cash Conversion Cycle history
YEARCash Conversion CycleYoY
99.74-49.21%
196.39-14.15%
228.77+18.69%
192.75-8.99%
211.79-9.45%
233.89+38.06%
169.41-4.50%
177.40+16.24%
152.61+15.97%
131.59-47.85%
252.32+64.86%
153.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech PLC is a healthcare company based in Bray, Ireland, with a focus on developing, manufacturing, and marketing medical diagnostic products. The company serves the clinical laboratory and point-of-care segments of the diagnostic market. Trinity Biotech employs 579 full-time staff and has been publicly traded since its IPO on October 21, 1992. Its products are designed to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two geographic segments: the Americas and Rest of World. Product categories include point-of-care diagnostics, emergency medicine diagnostics, clinical laboratory reagents, and blood bank screening. The company's point-of-care brands are Uni-Gold and Recombigen, while its emergency medicine diagnostics cover acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. Trinity Biotech supplies the clinical laboratory market with reagent products and other solutions through its clinical chemistry business. The blood bank screening division manufactures products to screen donated blood for transfusion-transmissible infections. The company's website is www.trinitybiotech.com. Trinity Biotech PLC is listed on the stock market under the ticker TRIB and ISIN US8964385046. The company's headquarters are located in Bray, Wicklow, Ireland. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Cash Conversion Cycle (CCC) of Trinity Biotech is 99.74 in 2025.

Cash Conversion Cycle (CCC) of Trinity Biotech changed from 196.39 to 99.74, representing a -49.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Trinity Biotech

All Key Metrics — Trinity Biotech